# Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C

> **NCT01899092** · PHASE1,PHASE2 · COMPLETED · sponsor: **Tacere Therapeutics, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** TT-034

## Key facts

- **NCT ID:** NCT01899092
- **Lead sponsor:** Tacere Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2016-09
- **Final completion:** 2016-11
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2016-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01899092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01899092, "Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01899092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*